ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Therapeu...
November 10 2009 - 5:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics, announced today that
several ImmunoGen poster presentations will be made at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics to be held in Boston, MA, on November 15-19,
2009.
"Our presentations at this Conference reflect key areas of focus
with our research team,” commented Daniel Junius, President and
Chief Executive Officer. “We’ll be reporting updated clinical data
with our IMGN901 compound when used for the treatment of
CD56-expressing solid tumors. This trial has now entered its
expansion phase and the findings reported will include the maximum
tolerated dose established. Additionally, ImmunoGen scientists will
be reporting data related to how compounds made with our engineered
linkers and maytansinoid cell-killing agents become activated once
inside the targeted cancer cells – findings that help inform our
product and our technology research programs. Our scientists also
will report data for a new family of cell-killing agents that we’re
developing that potentially further expands our product and
business development opportunities.”
ImmunoGen posters on Nov. 16,
12:30 – 2:30 PM
- “The effect of linker on target
cell catabolism and PK/PD of trastuzumab-maytansinoid conjugates”
(abstract #A149) at Poster session A; Drug Metabolism, Transport,
and Biodistribution.
ImmunoGen posters on Nov. 17,
12:30 – 2:30 PM
- “Clinical experience of IMGN901
(BB-10901, huN901-DM1) in patients with Merkel cell carcinoma
(MCC)” (abstract #B237) at Poster session B; Therapeutic Agents:
Biological 1.
- “Potent antigen-specific
anti-tumor activity observed with antibody-drug conjugates (ADCs)
made using a new class of DNA-crosslinking agents” (abstract #B126)
at Poster session B; Monoclonal Antibodies.
- “Designing potent antibody-drug
conjugates: The impact of lysosomal processing efficiency and
conjugate linker selection on anticancer activity” (abstract #B120)
at Poster session B; Monoclonal Antibodies.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cell-killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s proprietary cell-killing
agents specifically to cancer targets. In addition to the Company’s
product pipeline, compounds utilizing the TAP technology are in
clinical testing through ImmunoGen’s collaborations with Genentech
(a wholly-owned member of the Roche Group), sanofi-aventis, Biogen
Idec and Biotest. The most advanced compound, trastuzumab-DM1
(T-DM1), is in Phase III testing being conducted by Genentech
and Roche. Other ImmunoGen collaborative partners include Bayer
HealthCare and Amgen. More information about ImmunoGen can be found
at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024